Lupin, Ashok Leyland and TVS Motor to see some action today

Lupin Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 500257 | NSE: LUPIN

03 Sep 2020 Evaluate

Lupin has launched Leflunomide Tablets USP, 10 mg and 20 mg, having received an approval from the United States Food and Drug Administration (USFDA) earlier. The product would be manufactured at Lupin’s Pithampur (Unit I) facility in India. Leflunomide Tablets USP, 10 mg and 20 mg, is the generic equivalent of Arava Tablets, 10 mg and 20 mg, of Sanofi-Aventis U.S. LLC., and is indicated for the treatment of adults with active rheumatoid arthritis (RA). Leflunomide Tablets USP (RLD: Arava) had an annual sales of approximately $42 million in the U.S.

Ashok Leyland is planning to come up with multiple products for various segments as it aims to de-risk its business, which is currently skewed towards heavy and commercial vehicles. The Chennai-based commercial vehicle major is all set to introduce a new range of light commercial vehicles (LCVs) later this month and is also looking at electric mobility and products for the defence sector to drive its future growth.

TVS Motor Company has further invested a sum Rs 30 crore in Compulsorily Convertible Cumulative Preference Shares of Ultraviolette Automotive (UAPL). Consequent to the said investment, the company’s holding in UAPL increased to 29.48%. This investment is part of its latest round (Series B) of funding.

Tube Investments of India’s board has approved an additional investment of Rs 100 crore in CG Power and Industrial Solutions. The additional investment was being proposed to meet the funding requirements of CG Power and was subject to necessary corporate authorisations and statutory approvals. The Board of Directors of the company at the meeting held on September 2, 2020, has approved the same.

Intellect Design Arena has joined global banking standards organizations -- Banking Industry Architecture Network (BIAN), the non-profit organisation that promotes and provides a common framework for banking industry to help Revolutionise the API-Driven Contextual Banking Technology Framework.

Federal Bank and Innoviti Payment Solutions have entered into partnership to provide convenient and affordable options of Federal Bank Debit Cards through Innoviti POS terminals. This partnership will offer convenient EMI options to over 7.5 plus million Federal Bank Debit Card holders at over 70,000 plus Innoviti POS terminals across 1000 plus cities. Historically EMI options have been limited to credit cards and primarily used for purchases in durables and mobiles.

Bharat Petroleum Corporation (BPCL) has launched the country's first certified reference material for testing chemical components of crude oils. 'Bhartiya Nirdeshak Dravya', the first batch of the certified reference material, is approved by the National Physical Laboratory, New Delhi, which is under the Union science and technology ministry.

Lupin Share Price

2377.90 -81.85 (-3.33%)

08-May-2026 16:59 View Price Chart

Peers

Company Name	CMP
Sun Pharma Inds.	1847.30
Dr. Reddys Lab	1293.25
Cipla	1347.70
Zydus Lifesciences	938.90
Lupin	2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.